Clinical-stage vaccine developer using cell-free protein synthesis for pneumococcal conjugates
Vaxcyte engineers polyvalent pneumococcal conjugate vaccines (PCVs) using XpressCF®, a cell-free protein synthesis platform licensed from Sutro Biopharma. The company's lead candidate, VAX-31, is a 31-valent PCV in Phase 3 adult and Phase 2 infant trials—designed to cover more disease-causing serotypes than existing vaccines. The tech stack (Veeva QMS/Vault, SAP S/4HANA, HPLC, LC-MS, Azure) and active projects reveal a manufacturing-scale operation wrestling with process robustness, supply-chain security, and GCP compliance—signature challenges of transitioning from clinical to commercial manufacturing.
Notable leadership hires: Product Launch Lead, Logistics Director
Vaxcyte is a clinical-stage biotechnology company headquartered in San Carlos, California, focused on designing improved vaccines against bacterial pneumococcal disease. Founded in 2013, the company operates across three core vaccine programs: VAX-31 (31-valent PCV for adults and infants), VAX-24 (24-valent PCV for infants), and VAX-XL (earlier-stage, expanded-spectrum candidate). The company owns a proprietary cell-free protein synthesis platform called XpressCF® that enables manufacturing of complex, high-fidelity antigens. With 201–500 employees, Vaxcyte maintains parallel workstreams in clinical development, manufacturing scale-up, analytical validation, and regulatory compliance—hiring across research, engineering, manufacturing, and operations roles.
VAX-31, a 31-valent pneumococcal conjugate vaccine in Phase 3 adult trials and Phase 2 infant trials. It covers more serotypes than any PCV currently in clinical development.
XpressCF®, a cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. It differs from conventional cell-based production and is designed to accelerate vaccine development and improve immunological benefits.
Other companies in the same industry, closest in size
Vaxcyte's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.